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ABSTRACT
Background and Objectives: The renin-angiotensin-aldosterone system has been implicated in the pathogenesis of neo-
intimal hyperplasia, and a role for angiotensin II in the migration and proliferation of vascular smooth muscle cells in reste-
notic lesions has been proposed. The aim of this study was to determine the anti-proliferative and anti-inflammatory effects 
of ramiprilat-coated stents in a porcine coronary overstretch restenosis model. Subjects and Methods: Pigs were randomiz-
ed into two groups in which the coronary arteries {16 pigs (16 coronaries in each group)} had a 3.0×17 mm ramiprilat-coat-
ed MAC stent or a 3.0×17 mm control MAC stent (AMG, Munich, Germany) implanted with oversizing (stent-to-artery ra-
tio, 1.3 : 1) in porcine coronary arteries, and histopathologic analysis was assessed 28 days after stenting. Results: There were 
no significant differences in the injury and inflammation scores between the two groups (1.20±0.43 vs. 1.23±0.57, p=0.8; and 
1.21±0.39 vs. 1.25±0.49, p=0.6, respectively). Within the neointima, most inflammatory cells were lymphohistiocytes. Sig-
nificant positive correlations existed between inflammatory cell counts and the neointima areas (r=0.567, p<0.001), and be-
tween inflammatory cell counts and the percent area stenosis (r=0.478, p<0.001). There was no significant difference in the in-
flammatory cell counts normalized to the injury (110±89 vs. 123±83, p=0.4) and fibrin scores (0.15±0.06 vs. 0.17±0.07, p= 
0.8) between the 2 groups. There were trends toward a smaller neointima area (1.06±0.51 mm
2 vs. 1.28±0.35 mm
2, p=0.083) 
and a smaller percent area stenosis (18.9±8.7% vs. 21.8±7.2%, p=0.088) in the ramiprilat-coated stent group. Conclusion: 
Although the ramiprilat-coated stent did not show significant inhibitory effects on neointimal hyperplasia, the ramiprilat-
coated stent showed good effects on the inflammatory reaction and arterial healing similar to the control stent in a porcine co-
ronary restenosis model. (Korean Circ J 2011;41:535-541)
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Introduction
The mechanism underlying in-stent restenosis after stent 
implantation has been shown to principally involve neointi-
mal hyperplasia.
1-5) It has been reported that there is a strong 
correlation between the degree of vascular inflammation 
and neointimal formation.
6)7) The pathologic process of in-
stent restenosis is characterized by an inflammatory healing 
process after stretch and damage of the vessel wall.
7-9) 
The renin-angiotensin-aldosterone system has been im-536   Ramiprilat-Coated Stents and the Neointimal Reaction
plicated in the pathogenesis of neointimal hyperplasia, and a 
role for angiotensin II in the migration and proliferation of vas-
cular smooth muscle cells in restenotic lesions has been pro-
posed.
10) Moreover, administration of angiotensin converting 
enzyme inhibitors has been reported to reverse impaired en-
dothelium-dependent responses to acetylcholine in patients 
with heart failure
11) and hypertension,
12) and to improve coron-
ary endothelial function after treatment with an angiotensin 
converting enzyme inhibitor in patients with coronary artery 
disease.
13)
Our hypothesis in the present study was that the angioten-
sin-converting enzyme inhibitor ramiprilat-coated stent is ef-
fective in reducing neointimal hyperplasia and improving en-
dothelial function. We examined the anti-proliferative and 
anti-inflammatory effects of ramiprilat-coated stents in a por-
cine coronary overstretch restenosis model.
 
Subjects and Methods
Animal study protocol
This animal study was approved by the Ethical Committee 
of the Chonnam National University Hospital in Gwangju, 
Korea. The study animals were female swine weighing 22-35 
kg. To decrease acute thrombosis after stenting, pre-medica-
tion with aspirin (100 mg) and clopidogrel (75 mg) per day 
was given for 5 days before the procedure. On the procedure 
day, pigs were anesthetized with ketamine (20 mg/kg intra-
muscularly) and xylazine (2 mg/kg intramuscularly). The pigs 
received 3 liters/min of supplemental oxygen continuously 
through an oxygen mask. After 2% lidocaine was adminis-
tered subcutaneously at the cut-down site, the left carotid ar-
tery was surgically exposed, and a 7F sheath was inserted. 
Continuous hemodynamic and surface electrocardiographic 
monitoring was maintained throughout the procedure. Af-
ter heparin (5,000 uints) was administered intravenously as 
a bolus prior to the procedure, the target coronary artery was 
engaged using standard 7F guiding catheters and control 
angiograms of both coronary arteries were performed using 
non-ionic contrast agent in two orthogonal views. 
Coating method of ramiprilat into stents
A plasma polymerization reaction was performed to at-
tach an amine radical to the surface of MAC stents (AMG, Mu-
nich, Germany). A stent was fixed in a tubular reactor, which 
was made from a pyrex glass tube, then the pressure was dr-
opped to <5 mtorr by vacuum pump. For attachment of the 
amine radical to the stent surface, a diaminocyclohexane mo-
nomer was drifted to the tubular reactor at a constant dose 
(0.96 SCCM), and plasma was generated using a radiofre-
quency power generator. The power for polymerization of 
plasma was 100 W for 5 minutes, then 60 W for 15 minutes. 
A glass tube (7 cm in length and 1 cm in width) was boiled in 
water at 100°C for 5 minutes, then taken out and allowed to 
dry in an incubator. Two mL of ramiprilat solution was deliv-
ered to the glass tube, then the stent was immersed in the ra-
miprilat solution. The carboxy radical of ramiprilat was in-
troduced to the amine radical attached to the stent to form a 
covalent bond, and thus improved the attachment power be-
tween the stent and ramiprilat. This reaction was performed 
for 1 hour, then the stent was taken out and allowed to dry for 
>24 hours. For release kinetics of ramiprilat from the stent, 
the stent was placed in a glass vial and immersed in 100 mL 
of phosphate-buffered saline. The amount of coating of 
ramiprilat onto the surface of the stent was 90 µg/stent, and 
the median thickness of coating was 1 µm. The amount of ra-
miprilat released to the buffer solution was measured using 
an absorbance test for ultraviolet at 278 nm (Fig. 1). The rami-
prilat coating on the surface of the stent was confirmed by sc-
anning electron microscopy (Fig. 2).
Stent-induced stenosis
Pigs were randomized into two groups in which the coro-
nary arteries {16 pigs (16 coronaries in each group)} had a 
3.0×17-mm ramiprilat-coated MAC stent or a 3.0×17-mm 
control MAC stent implanted for proximal epicardial coro-
nary arteries. The stent was deployed by inflating the balloon 
to nominal pressure at the injury site and the resulting stent-
to-artery ratio was 1.3 : 1. Repeat angiograms were obtained 
immediately after stent implantation. Then, all equipment 
was removed and the carotid artery was ligated. All animals 
received 100 mg of aspirin and 75 mg of clopidogrel orally 
each day until death. Twenty-eight days after stenting, the ani-
mals underwent repeat angiography in the same orthogonal 
views before death and a 20 mL intracoronary injection of 
potassium chloride was administered. The hearts were remov-
ed, and the coronary arteries were pressure-perfusion fixed at 
70 mmHg in 10% neutral buffered formalin overnight. The 
arteries were step-sectioned, and processed routinely for light 
microscopy.
Fig. 1. In vitro screening of ramiprilat release from stent surfaces. 
The amount of ramiprilat released to buffer solution was meas-
ured using an absorbance test for ultraviolet at 278 nm.
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Histopathologic analysis
Histopathologic evaluation of each artery was performed 
by an experienced cardiovascular pathologist. The specimens 
were embedded in methylmethacrylate and sections were 
cut with a low-speed diamond wafer mounted to a Buehler 
Isomet saw (Buehler Ltd., Lake Bulff, IL, USA) leaving the stent 
Fig. 2. Scanning electron microscopic findings after ramiprilat coating on the surface of the stent (magnification left top: ×30, right top: 
×150, left bottom: ×250, right bottom: ×500).
Fig. 3. The hematoxylin-eosin stain (magnitude ×20) in ramiprilat-coated (A) and control bare-metal stent (B) groups. Note that neointimal 
overage of stent struts tended to be smaller in the ramiprilat-coated stent group compared with the control bare-metal stent group.
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wires intact in the cross sections to minimize potential arti-
facts from removal of the stent wires. Fifty to 100 µm sec-
tions were obtained approximately 1 mm apart and stained 
with hematoxylin-eosin for histologic analysis (Fig. 3). Mea-
surements of the histopathologic sections were performed us-
ing a calibrated microscope, digital video imaging system, and 
microcomputer program (Visus 2000 Visual Image Analysis 
System, IMT Tech, CA, USA) Borders were manually traced 
for lumen area, area circumscribed by the internal elastic la-
mina, and the innermost border of the external elastic lamina 
(external elastic lamina area). Morphometric analysis of the 
neointimal area for a given vessel was calculated as the mea-
sured internal elastic lamina area minus the lumen area. The 
measurements were made on five cross sections from the pro-
ximal and distal ends and the three midpoints of each stented 
segments. Histopathologic stenosis was calculated as 100× 
{1-(lesion lumen area/lesion internal elastic lamina area)}. Fi-
brin was identified on hematoxylin and eosin-and Carstair’s 
histochemical-stained sections (Fig. 4).
 
Evaluation of arterial injury
Arterial injuries at each strut site were determined by the 
anatomic structures penetrated by each strut. A numeric val-
ue was assigned, as previously described by Schwartz et al.
14) 
0=no injury; 1=break in the internal elastic membrane; 2= 
perforation of the media; and 3=perforation of the external 
elastic membrane to the adventitia. The average injury score 
for each segment was calculated by dividing the sum of the 
injury scores by the total number of struts at the examined 
section. 
 
Evaluation of inflammation and fibrin scores
With respect to the inflammation score for each individu-
al strut, the grading was as follows: 0=no inflammatory cells 
surrounding the strut; 1=light, non-circumferential lympho-
histiocytic infiltrate surrounding the strut; 2=localized, mo-
derate-to-dense cellular aggregate surrounding the strut non-
circumferentially; and 3=circumferential dense lymphohis-
tiocytic cell infiltration of the strut. The inflammation score 
for each cross section was calculated by dividing the sum of 
the individual inflammation scores by the total number of 
struts at the examined section. Inflammatory cell counts were 
normalized to the injury score in the neointima. The number 
of uncovered struts (defined as no coverage by any tissue, ex-
cept the thrombus or fibrin-platelet complex) was recorded. 
Arterial healing was assessed by fibrin deposition and ordi-
nal data for fibrin were collected on each stent section using 
a scale of 0-3, as previously reported.
15) 
Statistical analysis
The Statistical Package for the Social Sciences (SPSS) for 
Windows (version 15.0; SPSS Inc., Chicago, IL, USA) was used 
for all analyses. Continuous variables were presented as the 
mean value±SD; comparisons were conducted by Student’s 
A  
B  
Fig. 4. The Carstair’s fibrin stain (left: magnitude ×20, right: magnitude ×200) in ramiprilat-coated (A) and control bare-metal stent (B) 
groups. Fibrin deposition (reddish-orange stain) is noted around the stent struts.Young Joon Hong, et al.   539
t-test or the Wilcoxon rank-sum test if the normality assump-
tion was violated. Pearson’s correlation coefficient was used 
to determined the correlations between the inflammatory cell 
counts and the neointimal area, and between the inflammato-
ry cell counts and the percent area stenosis. A value of p<0.05 
was considered statistically significant. 
 
Results
Procedural characteristics
One 3.0×17 mm ramiprilat-coated MAC stent or one 
3.0×17 mm control MAC stent were placed for 1 epicardial 
coronary artery per pig. A total of 32 stents were placed in 
the proximal left anterior descending, proximal left circum-
flex, and proximal right coronary arteries for 32 pigs (Table 1). 
The mortality for this study was zero. Quantitative coronary 
angiography before and after stent implantation showed the 
stent-to-artery diameter ratio to be 1.323±0.089. There was 
no significant difference in the stent-to-artery ratio between 
the ramiprilat-coated control bare-metal stent groups.
 
Injury and inflammation scores 
There were no significant differences in injury and inflam-
mation scores between the ramiprilat-coated and control 
bare-metal stent groups (Table 2). Within the neointima, 
most inflammatory cells were lymphohistiocytes. Significant 
positive correlations existed between the inflammatory counts 
and the neointima area and between the inflammatory counts 
and the percent area stenosis (Fig. 5). 
 
Inflammatory reaction, fibrin score, and neointimal 
reaction
There was no significant difference in the inflammatory cell 
counts normalized to the injury score between the ramiprilat-
coated and control bare-metal stent groups (Fig. 6). There was 
no significant difference in fibrin scores between the ramipri-
lat-coated and control bare-metal stent groups (Fig. 7). There 
was a trend toward a smaller neointima area and a smaller per-
cent area stenosis in the ramiprilat-coated stent group com-
pared with the control bare-metal stent group (Table 2). Un-
covered struts did not exist in the ramiprilat-coated and con-
trol bare-metal stent groups.
Discussion
This study demonstrated that ramiprilat-coated stents did 
not have significant inhibitory effects on neointimal hyper-
plasia; however, ramiprilat-coated stents had good effects on 
the inflammatory reaction and arterial healing similar to con-
trol stents in a porcine coronary restenosis model.
Drug-eluting stents were developed in an effort to reduce 
the rate of restenosis. Anti-restenotic drugs (sirolimus or pa-
clitaxel) are released over a period as short as days to as long 
Table 1. Stented porcine coronary arteries
Ramiprilat-
coated stent 
(n=16)
Control bare-
metal stent 
(n=16)
p
Left anterior descending 
  artery
7 6 0.8
Left circumflex artery 6 7 0.8
Right coronary artery 3 3 1.0
Table 2. Coronary artery morphometric measurements 
Ramiprilat-
coated stent 
(n=16)
Control bare-
metal stent 
(n=16)
p 
Injury score 1.20±0.43 1.23±0.57 0.80
Inflammation score 1.21±0.39 1.25±0.49 0.60
IEL area (mm
2) 5.39±1.06 5.76±0.82 0.18
Lumen area (mm
2) 4.33±1.05 4.48±0.92 0.60
Neointima area (mm
2) 1.06±0.51 1.28±0.35 0.08
Area stenosis (%) 18.9±8.70 21.8±7.20 0.08
IEL: internal elastic lamina
Fig. 5. Correlations between the inflammatory counts and neointimal area (A) and between the inflammatory counts and percent area ste-
nosis (B). Significant positive correlations existed between the inflammatory counts and the neointima area, and between the inflammatory 
counts and the percent area stenosis.
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as 1 year after implantation to reduce the local proliferative 
healing response. However, previous studies have suggested 
that drug-eluting stents affect poor endothelialization
16)17) and 
delayed arterial healing, which are associated with endothe-
lial dysfunction and inflammation leading to stent thrombo-
sis.
16)18)19) The endothelium is a single layer of endothelial cells 
lining the vascular wall and plays an integral part in mainta-
ining vascular homeostatsis. However, stenting causes sig-
nificant injury to the vascular wall and endothelium result-
ing in a proliferative response of the vessel wall and the de-
velopment of neointimal hyperplasia, and this phenomenon 
correlates in humans with the plasma angiotensin-convert-
ing enzyme concentration.
20)21) Furthermore, tissue angioten-
sin-converting enzyme is up-regulated locally during the vas-
cular healing process.
22) Angiotensin-converting enzyme in-
hibition is thought to potentially contribute to the preven-
tion of tissue angiotensin-converting enzyme up-regulation 
after stent implantation.
Stimulation of angiotensin II type 1 receptors after arterial 
injury during balloon angioplasty or stenting procedures pro-
motes vascular smooth muscle cell migration,
23) prolifera-
tion
24-26) and extracellular matrix production,
27) with the in-
tent to block this receptor by angiotensin-converting enzyme 
inhibitors or specific angiotensin II type 1 receptor antago-
nists and thereby reduce restenosis.
28)29) 
In the present study, ramiprilat-coated stents did not show 
marked anti-proliferative effects compared to control bare-
metal stent, as reported previously using other drug-eluting 
stents, such as sirolimus-, paclitaxel-, or zotarolimus-eluting 
stents. However, ramiprilat-coated stents had good anti-in-
flammatory effects and promoted arterial healing compared 
to control bare-metal stents. 
There were several limitations in the current study. First, it 
remains to be established whether or not our findings in nor-
mal, non-atherosclerotic porcine coronary arteries stimulat-
ed with oversized stents for neointimal proliferation can be 
extrapolated to human clinical situations with pre-existing 
atherosclerosis and stent sizes matched to the reference ves-
sel. Second, our study did not examine the early inflammato-
ry response, as there is little neointimal formation at that time. 
Third, we examined inflammation based on hematoxylin and 
eosin histologic findings. It would be more appropriate and 
accurate to utilize immunohistochemistry techniques, which 
are the standard for such studies, and with appropriate tech-
niques can be used on resin-embedded sections. Fourth, we 
did not perform long-term follow-up experiments to exam-
ine late neointimal reactions, late inflammatory responses, 
and arterial healing. Fifth, we only used a single dose of rami-
prilat for stent coating. In the future, a study using higher 
doses of ramiprilat coating onto the stent struts is needed.
In conclusion, although ramiprilat-coated stents did not 
show significant inhibitory effects with respect to neointimal 
hyperplasia, there were good effects on inflammatory reac-
tions and arterial healing similar to control stents in a porcine 
coronary restenosis model. 
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